The goal of this study was to review relevant case-control studies to determine the association of tumor necrosis factor-α (TNF-α) gene polymorphisms and coronary artery disease (CAD) susceptibility.
Methods
Using appropriate keywords, we identified relevant studies using PubMed, Cochrane, Embase, CNKI, VANFUN, and VIP. Key pertinent sources in the literature were also reviewed, and all articles published through April 2019 were considered for inclusion. Based on eligible studies, we performed a meta-analysis of association between 308G/A, 238G/A, 857C/T, 863C/A and 1031 T/C polymorphisms in TNF-α and risk of CAD.
Results
We found 25 studies that were consistent with this meta-analysis, including 7697 patients in the CAD group and 9655 control patients. TNF-α 308G/A locus A showed no significant association with CAD susceptibility by the five models in the analysis of the overall population, European, African, South Asian, and North Asian patients. TNF-α 863C/A locus A and 1031 T/C locus C exhibited no significant association with CAD susceptibility. TNF-α 238G/A locus A had no significant association with CAD susceptibility in the overall population. However, TNF-α 238G/A locus A showed significant association with higher CAD susceptibility in the subgroup of Europeans and north Asians. TNF-α 857C/T locus T had no significant association with CAD susceptibility in the analysis of the overall population and Europeans. In the north Asian population, TNF-α 857C/T locus T was associated with lower CAD susceptibility by the heterozygote model.
Conclusion
TNF-α 308G/A, 857C/T, 863C/A, and 1031 T/C has no significant association with CAD susceptibility. TNF-α 238G/A locus A has significant association with CAD susceptibility in Europeans and north Asians, but has no significant association in the overall population. Studies with a larger sample size are required to confirm the association between TNF-α 238G/A and CAD susceptibility.
Hinweise
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
ACS
Acute coronary syndrome
AS
Atherosclerosis
CAD
Coronary artery disease
HWE
Hardy-Weinberg equilibrium
NOS
Newcastle–Ottawa Scale
PICOS
Participants, Interventions, Comparisons, Outcomes and Study design
TNF
Tumor necrosis factor
TNF-α
Tumor necrosis factor-α
Background
Coronary artery disease (CAD) refers to a heart disease caused by ischemia and hypoxia of myocardial cells following coronary artery stenosis or blockage due to coronary atherosclerosis (AS). Globally, CAD is an important cause of mortality and morbidity, with approximately 9 million deaths between 2007 and 2017 [1]. At present, the major risk factors for CAD confirmed in clinical studies include age, gender, poor diet and lifestyle habits, metabolic syndrome (including obesity or overweight, hypertension, type 1 or type 2 diabetes and dyslipidemia), smoking, drinking, psychosocial factors and genetic factors. Studies [2, 3] showed that the risk of developing CAD in an individual is modulated by an interplay between genetic and lifestyle factors. In the future, genetic testing can be expected to enable precision medicine approaches by identifying subgroups of patients at increased risk of CAD or those with a specific driving pathophysiology in whom a therapeutic or preventive approach is most useful.
Tumor necrosis factor (TNF) is a proinflammatory cytokine in vivo with extensive biological activities. Human TNF gene, located in the short arm of chromosome 6, is a 7 kb DNA sequence composed of TNFA and TNFB, encoding TNF-α and TNF-β, respectively, each containing 4 exons and 3 introns. At present, many scholars agree that there is an interactive feedback loop between acute or chronic inflammatory reactions, the dynamics of atherosclerotic plaques, platelet aggregation, activation of the coagulation system and lipid metabolism disorders. Inflammatory response may be an important trigger mechanism, and there are many kinds of inflammatory biomarkers in serum, including C-reactive protein, intercellular adhesion molecule, p-selectin, amyloid A protein, fibrinogen, e-selectin, pregnancy-related plasma protein-a, serum interleukin-6, and TNF-α [4‐6]. Studies have shown that the presence of TNF-α gene polymorphism may affect gene transcription and expression levels, and is associated with a variety of diseases such as rheumatoid arthritis, type 1 diabetes, type 2 diabetes, ankylosing spondylitis, sarcoidosis, and silicosis [7‐9]. The aim of this study was to perform a meta-analysis of all available literature to obtain updated evidence about association between TNF-α polymorphisms and CAD susceptibility.
Anzeige
Methods
Search strategy
To identify studies pertaining to the associations between 308G/A, 238G/A, 857C/T, 863C/A and 1031 T/C polymorphisms in TNF-α and risk of CAD, we reviewed the Cochrane library, PubMed, Embase, CNKI, VANFUN, and VIP databases for relevant articles published through April 2019. We also reviewed the references of all identified articles to look for additional studies. Search terms were as follows: gene polymorphisms, gene, polymorphism, variant, genotype, tumor necrosis factor-α, TNF-α, coronary artery disease, CAD, angina, myocardial infarction, ischemic heart disease, tumor necrosis factor and TNF. These terms were used in combination with “AND” or “OR”. This literature review was performed independently by two investigators, with a third resolving any disputes as needed. The detailed search strategy of PubMed: (“gene polymorphisms” or “gene” or “polymorphism” or “variant” or “genotype”) and (“tumor necrosis factor-α” or “TNF-α” or “tumor necrosis factor” or “TNF”) and (“coronary artery disease” or “CAD” or “angina” or “myocardial infarction” or “ischemic heart disease”) AND Humans [Mesh]Search.
Following the PICOS (Participants, Interventions, Comparisons, Outcomes and Study design) principle, the key search terms included (P) patients with CAD; (I) detection the gene polymorphisms of TNF-α; (C/O) compare the gene polymorphisms of TNF-α between the CAD group and the control group; (S) case-control studies or cohort study.
Study selection criteria
Eligible studies met the following criteria: [1] case-control or cohort studies [2]; the subjects in the case group were patients with CAD [3]; the participants in the control group did not have CAD [4]; 308G/A, 238G/A, 857C/T, 863C/A and 1031 T/C of TNF-α were studied; 4) English or Chinese language.
Studies were excluded for meeting the following criteria: [1] duplicate articles or results [2]; apparen tdata errors [3]; case reports, theoretical research, conference reports, systematic reviews, meta-analyses, and other forms of research or comment not designed in a randomized controlled manner [4]; irrelevant outcomes [5]; lack of a control group.
Anzeige
Two investigators independently determined whether studies met the inclusion criteria, with a third resolving any disputes as needed.
Data extraction and quality assessment
For each included study, two categories of information were extracted: basic information and primary clinical outcomes. Basic information relevant to this meta-analysis included: author names, year of publication, country, ethnicity, and sample size. Primary outcomes relevant to this analysis included frequency of genotypes (308G/A, 238G/A, 857C/T, 863C/A and1031T/C of TNF-α) in the CAD group and the control group. This data extraction was performed independently by two investigators, with a third resolving any disputes as needed.
We used Newcastle–Ottawa Scale (NOS) to assess the quality of eligible studies. The version of case-control studies included a set of questions: adequacy of case definition, representativeness of cases, selection of controls, definition of controls, matched age and sex, additional factors, ascertainment of exposure, case and controls (the same ascertainment method), cases and control (the same non-response rate).
Statistical analysis
STATA v12.0 (TX, USA) was used for all analyses. Heterogeneity in study results was assessed using chi-squared and I2tests and appropriate analytic models (fixed-effects or random-effects) were determined. A chi-squared P ≤ 0.05 and an I2 > 50% indicated high heterogeneity and the random-effects model was used in this case. A chi-squared P > 0.05 and an I2 ≤ 50% indicated acceptable heterogeneity and the fixed-effects model was used. Egger’s test and Begg’s test were used to determine whether there was publication bias. Under ideal conditions (such as random mating, no selection, mutation, or migration), if the population is in line with the Hardy-Weinberg equilibrium (HWE), the proportion of certain characteristic genes will remain unchanged in inheritance. HWE is closely related to genotyping quality. HWE is a common hypothesis. In the meta-analysis of genetic association study, it is necessary to test whether the genotype distribution of the control group conforms to HWE. If the HWE genetic balance test was not provided in the original text or not performed on the control group, we used Stata v12.0 to carry out manual detection and extracted the corresponding results (P value). Five commonly used gene models were selected for meta-analysis: the allelic model (A vs. C); homozygote model (AA vs. CC); heterozygote model (AC vs. CC); dominant model (AA + ACvs.CC); regressive model (AA vs. AC+ CC). OR and 95% CI were used to analyze all the indexes.
Results
Overview of included studies
We reviewed a total of 1115 articles identified by our initial keyword search, of which 1026 were excluded following title/abstract review. The complete full texts of the remaining 89 articles were assessed, excluding 64 articles that did not meet the study inclusion criteria. Reasons for exclusion of these studies were theoretical research [3], lack of clinical outcomes [10], duplicate articles [5], and lack of a control group [11]. We ultimately identified a total of 25 case-control studies [10‐34] that met the inclusion criteria for this meta-analysis, including 7697 patients in the CAD group and 9655 in the control group. The study selection process is outlined in Fig. 1. Table 1 summarizes the basic information for each study, including author names, year of publication, country, ethnicity, and sample size. Seven studies involved Eurpeans, 14 involved north Asians, 3 involved south Asians, 2 involved Africans, and 1 involved North Americans. The risk of bias assessed by NOS is presented in Fig. 2.
Table 1
The basic characteristics description of included studies
Meta-analysis of TNF-α308G/a polymorphisms and CAD susceptibility
In total, 19 studies with 7036 patients in the CAD group and 8940 controls reported on the association between TNF-α 308G/A and CAD susceptibility. For studies without significant heterogeneity (chi-squared P > 0.05 and I2 < 50%), the fixed-effects model was chosen to analyze the all the comparison models except the dominant model and allelic model in the subgroup analysis of South Asians. The results of Begg’s test (p > 0.05) suggested that there was no significant publication bias among the study results.
The results showed that TNF-α 308G/A locus A had no significant association with CAD susceptibility: the allelic model (A vs. G) (OR:1.047, 95% CI:0.973–1.126); the homozygote model (AA vs. GG) (OR:1.106,95% CI:0.888–1.377); the dominant model (AA + GA vs. GG) (OR: 1.046,95% CI:0.963–1.136); the regressive model (AA vs.GA + GG) (OR: 1.102,95% CI: 0.886–1.370); the heterozygote model (GA vs. GG) (OR: 1.037,95%CI:0.950–1.131). In the subgroup analysis, there was no significant association between TNF-α 308G/A locus A and CAD by the five models.
All the above results are presented in Fig. 3, Fig. 4 and Table 2.
Table 2
Meta-analysis of TNF-α 308G/A polymorphisms and CAD susceptibility
Genetic Model
Subgroup analysis
N (case/control)
OR(95% CI)
P*
I2
P#
P value
Begg
Egger
AA vs GG + GA
overall
6522/8196
1.102 (0.886,1.370)
0.209
22.0%
0.383
0.322
0.106
European
2472/4076
1.118 (0.810,1.544)
0.087
45.7%
0.496
0.881
0.102
North Asian
3322/3332
1.135 (0.821,1.570)
0.349
10.0%
0.443
0.624
0.907
African
418/406
0.705 (0.320,1.553)
–
–
0.385
–
–
South Asian
310/382
3.880 (0.401,37.525)
0.894
0.0%
0.242
0.317
–
HWE
5814/7737
1.096 (0.835,1.438)
0.210
23.1%
0.510
0.329
0.042
NO HWE
708/459
1.112 (0.773,1.601)
0.127
57.1%
0.567
0.317
–
AA+GA vs GG
overall
6522/8196
1.046(0.963,1.136)
0.151
24.8%
0.290
0.770
0.973
European
2472/4076
1.008 (0.899,1.130)
0.390
4.8%
0.890
0.881
0.804
North Asian
3322/3332
1.065 (0.927,1.222)
0.143
33.1%
0.374
0.128
0.138
African
418/406
1.109 (0.833,1.476)
–
–
0.478
–
–
South Asian
310/382
1.352 (0.839,2.179)
0.046
74.8%
0.216
0.317
–
HWE
5814/7737
1.033 (0.948,1.126)
0.175
23.6%
0.459
0.791
0.972
NO HWE
708/459
1.219 (0.896,1.658)
0.152
51.3%
0.208
0.317
–
AA vs GG
overall
6522/8196
1.106 (0.888,1.377)
0.226
20.5%
0.367
0.373
0.132
European
2472/4076
1.105 (0.798,1.530)
0.118
41.0%
0.548
0.453
0.097
North Asian
3322/3332
1.147 (0.829,1.587)
0.274
22.1%
0.407
0.624
0.822
African
418/406
0.739 (0.333,1.638)
–
–
0.456
–
–
South Asian
310/382
4.018 (0.415,38.903)
0.869
0.0%
0.230
0.317
–
HWE
5814/7737
1.088 (0.828,1.431)
0.234
20.8%
0.545
0.329
0.048
NO HWE
708/459
1.138 (0.790,1.641)
0.121
58.5%
0.488
0.317
–
GA vs GG
overall
6522/8196
1.037 (0.950,1.131)
0.258
15.7%
0.418
0.673
0.958
European
2472/4076
0.999 (0.887,1.124)
0.352
10.1%
0.981
0.881
0.707
North Asian
3322/3332
1.049 (0.903,1.218)
0.288
16.9%
0.531
0.531
0.398
African
418/406
1.154 (0.859,1.549)
–
–
0.179
–
–
South Asian
310/382
1.281 (0.790,2.076)
0.061
71.4%
0.315
0.317
–
HWE
5814/7737
1.027 (0.940,1.122)
0.226
19.1%
0.557
0.850
0.671
NO HWE
708/459
1.389 (0.839,2.298)
0.641
0.0%
0.201
0.317
–
A vs G
overall
6522/8196
1.047 (0.973,1.126)
0.065
34.7%
0.222
0.721
0.673
European
2472/4076
1.017 (0.920,1.124)
0.303
16.6%
0.741
0.453
0.312
North Asian
3322/3332
1.071 (0.947,1.211)
0.071
43.1%
0.276
0.128
0.120
African
418/406
1.043 (0.816,1.332)
–
–
0.636
–
–
South Asian
310/382
1.400 (0.887,2.210)
0.037
77.0%
0.149
0.317
–
HWE
5814/7737
1.034 (0.957,1.116)
0.122
28.9%
0.399
0.850
0.628
NO HWE
708/459
1.172 (0.927,1.481)
0.039
76.6%
0.185
0.317
–
*P value of Heterogeneity chi-squared
#P value of Pooled statistic
×
×
Anzeige
Meta-analysis of TNF-α 238G/a polymorphisms and CAD susceptibility
In total, 12 studies with 5167 patients in the CAD group and 7103 controls reported on the association of TNF-α 238G/A and CAD susceptibility. For studies without significant heterogeneity (chi-squared P > 0.05 and I2 < 50%), the fixed-effects model was chosen to analyze the all the comparison models except the dominant model and the heterozygote model in the subgroup analysis of the overall population, north Asians and HWE, and the allelic model in the subgroup analysis of HWE. The results of Begg’s test (p > 0.05) suggested that there was no significant publication bias among the study results.
The results showed that TNF-α 238G/A locus A had no significant association with CAD susceptibility: the allelic model (A vs. G) (OR:1.088, 95% CI:0.950–1.244); the homozygote model (AA vs. GG) (OR:1.506, 95% CI:0.835–2.715); the dominant model (AA + GA vs. GG) (OR: 1.072, 95% CI:0.931–1.235); the regressive model (AA vs. GA + GG) (OR: 1.437, 95% CI: 0.821–2.662); the heterozygote model (GA vs GG) (OR: 1.165, 95% CI:0.914–1.485).
In the subgroup analysis, TNF-α 238G/A locus A showed significant association with higher CAD susceptibility in the subgroup of Europeans: the homozygote model (AA vs. GG) (OR:2.961, 95% CI:1.113–7.9879); the regressive model (AA vs. GA + GG) (OR: 2.985, 95% CI: 1.121–7.946). TNF-α 238G/A locus A had significant association with higher CAD susceptibility in the subgroup of HWE: the homozygote model (AA vs. GG) (OR:2.838, 95% CI:1.260–6.394); the regressive model (AA vs. GA + GG) (OR: 2.832, 95% CI: 1.258–6.375).TNF-α 238G/A locus A exhibited significant association with higher CAD susceptibility in the subgroup of North Asian: the dominant model (AA + GA vs. GG) (OR:1.231, 95% CI:1.010–1.500).TNF-α 238G/A locus A displayed significant association with higher CAD susceptibility in the subgroup of no HWE: the dominant model (AA + GA vs. GG) (OR: 1.686, 95% CI:1.060–2.681); the heterozygote model (GA vs. GG) (OR: 2.265, 95% CI:1.307–3.926).
All the above results are presented in Fig. 5 and Table 3.
Table 3
Meta-analysis of TNF-α 238G/A polymorphisms and CAD susceptibility
Genetic Model
Subgroup analysis
N (case/control)
OR(95%CI)
P*
I2
P#
P value
Begg
Egger
AA vs GG + GA
overall
4827/6875
1.478 (0.821,2.662)
0.624
0.0%
0.193
0.161
0.034
European
2108/3686
2.985 (1.121,7.946)
0.691
0.0%
0.209
0.624
0.902
North Asian
2522/2785
0.947 (0.443,2.023)
0.659
0.0%
0.888
0.188
0.038
HWE
3934/5941
2.832 (1.258,6.375)
0.903
0.0%
0.012
0.677
0.848
NO HWE
696/530
0.602 (0.236,1.537)
0.721
0.0%
0.289
0.317
–
AA+GA vs GG
overall
4827/6875
1.072 (0.931,1.235)
0.033
46.6%
0.331
0.300
0.041
European
2108/3686
0.929 (0.758,1.138)
0.375
5.6%
0.475
0.327
0.440
North Asian
2522/2785
1.231 (1.010,1.500)
0.044
51.5%
0.040
0.621
0.148
HWE
3934/5941
1.020 (0.879,1.184)
0.052
45.0%
0.791
0.186
0.110
NO HWE
696/530
1.686 (1.060,2.681)
0.586
0.0%
0.027
0.317
–
AA vs GG
overall
4827/6875
1.506 (0.835,2.715)
0.658
0.0%
0.173
0.161
0.033
European
2108/3686
2.961 (1.113,7.879)
0.691
0.0%
0.030
0.624
0.927
North Asian
2522/2785
0.980 (0.458,2.097)
0.680
0.0%
0.958
0.188
0.037
HWE
3934/5941
2.838 (1.260,6.394)
0.934
0.0%
0.012
0.677
0.893
NO HWE
696/530
0.629 (0.246,1.608)
0.705
0.0%
0.333
0.317
–
GA vs GG
overall
4827/6875
1.165 (0.914,1.485)
0.007
56.2%
0.218
0.100
0.040
European
2108/3686
0.890 (0.706,1.121)
0.343
11.1%
0.322
0.327
0.391
North Asian
2522/2785
1.409 (0.981,2.024)
0.014
60.2%
0.063
0.805
0.160
HWE
3934/5941
1.053 (0.837,1.325)
0.039
47.6%
0.659
0.186
0.156
NO HWE
696/530
2.265 (1.307,3.926)
0.651
0.0%
0.004
0.317
–
A vs G
overall
4827/6875
1.088 (0.950,1.244)
0.096
35.8%
0.222
0.246
0.040
European
2108/3686
0.979 (0.807,1.189)
0.416
0.0%
0.833
0.142
0.509
North Asian
2522/2785
1.201 (0.995,1.450)
0.084
44.1%
0.057
0.805
0.117
HWE
3934/5941
1.055 (0.914,1.217)
0.077
40.7%
0.465
0.243
0.087
NO HWE
696/530
1.377 (0.918,2.065)
0.538
0.0%
0.122
0.317
–
*P value of Heterogeneity chi-squared
#P value of Pooled statistic
×
Anzeige
Meta-analysis of TNF-α 857C/T polymorphisms and CAD susceptibility
In total, 9 studies with3843 patients in the CAD group and 5616 in the control group reported on the association of TNF-α 857C/T and CAD susceptibility. For studies with no significant heterogeneity (chi-squared test P > 0.05 and I2 < 50%), the fixed-effects model was chosen to analyze all the comparison models. The results of Begg’s test (p > 0.05) revealed no significant publication bias among the study results.
The results showed no significant association between TNF-α 857C/T locus T and CAD susceptibility: the allelic model (T vs. C) (OR:0.949, 95% CI:0.862–1.045); the homozygote model (TT vs. CC) (OR:1.105, 95%CI:0.820–1.488); the dominant model (TT + CT vs. CC) (OR: 0.920, 95% CI:0.825–1.027); the regressive model (TTvs.CC+ CT) (OR: 1.124, 95% CI: 0.836–1.510); the heterozygote model (CT vs. CC) (OR: 0.904, 95% CI:0.807–1.012). In the subgroup analysis, there was no significant association between TNF-α 857C/T and CAD by the five models in Europeans, HWE and no HWE. In the north Asian population, TNF-α 857C/T locus T was associated with lower CAD susceptibility by the heterozygote model (CT vs. CC) (OR: 0.812, 95% CI:0.676–0.976), the dominant model (TT + CT vs. CC) (OR: 0.835, 95% CI:0.701–0.996);
All the above results are presented in Fig. 6 and Table 4.
Table 4
Meta-analysis of TNF-α 857C/T polymorphisms and CAD susceptibility
Genetic Model
Subgroup analysis
N (case/control)
OR(95%CI)
P*
I2
P#
P value
Begg
Egger
TT vs CC + CT
overall
3494/5279
1.124 (0.836,1.510)
0.437
0.0%
0.440
1.000
0.769
European
2139/3566
1.135 (0.753,1.710)
0.752
0.0%
0.546
0.624
0.577
North Asian
1158/1309
1.112 (0.726,1.703)
0.132
43.5%
0.627
0.624
0.994
HWE
1844/3078
1.230 (0.866,1.748)
0.466
0.0%
0.247
0.881
0.960
NO HWE
1453/1797
0.901 (0.519,1.564)
0.305
15.9%
0.711
0.602
0.839
TT + CT vs CC
overall
3494/5279
0.920 (0.825,1.027)
0.357
9.2%
0.137
0.283
0.467
European
2139/3566
0.978 (0.851,1.125)
0.498
0.0%
0.758
0.327
0.810
North Asian
1158/1309
0.835 (0.701,0.996)
0.327
13.7%
0.045
0.624
0.992
HWE
1844/3078
0.909 (0.793,1.041)
0.230
26.1%
0.167
0.881
0.641
NO HWE
1453/1797
0.942 (0.784,1.132)
0.428
0.0%
0.524
0.117
0.006
TT vs CC
overall
3494/5279
1.105 (0.820,1.488)
0.368
8.0%
0.513
0.858
0.833
European
2139/3566
1.140 (0.755,1.721)
0.704
0.0%
0.534
0.624
0.643
North Asian
1158/1309
1.067 (0.693,1.644)
0.109
47.1%
0.767
0.624
0.972
HWE
1844/3078
1.209 (0.848,1.724)
0.383
5.8%
0.295
0.881
0.996
NO HWE
1453/1797
0.890 (0.511,1.547)
0.291
19.1%
0.679
0.602
0.872
CT vs CC
overall
3494/5279
0.904 (0.807,1.012)
0.605
0.0%
0.081
0.474
0.429
European
2139/3566
0.966 (0.836,1.116)
0.610
0.0%
0.637
0.327
0.689
North Asian
1158/1309
0.812 (0.676,0.976)
0.649
0.0%
0.026
1.000
0.695
HWE
1844/3078
0.881 (0.765,1.015)
0.466
0.0%
0.080
0.652
0.632
NO HWE
1453/1797
0.946 (0.782,1.145)
0.513
0.0%
0.569
0.602
0.247
T vs C
overall
3494/5279
0.949 (0.862,1.045)
0.181
28.6%
0.288
0.371
0.496
European
2139/3566
0.994 (0.878,1.126)
0.442
0.0%
0.926
0.624
0.901
North Asian
1158/1309
0.886 (0.762,1.032)
0.108
47.2%
0.119
1.000
0.718
HWE
1844/3078
0.952 (0.846,1.071)
0.109
42.2%
0.416
0.652
0.796
NO HWE
1453/1797
0.943 (0.798,1.114)
0.330
9.7%
0.490
0.117
0.223
*P value of Heterogeneity chi-squared
#P value of Pooled statistic
×
Meta-analysis of TNF-α 863C/a polymorphisms and CAD susceptibility
In total, 10 studies with3225 patients in the CAD group and 4784 controls reported on the association of TNF-α 863C/A and CAD susceptibility. For studies with no significant heterogeneity (chi-squared test, P > 0.05 and I2 < 50%), the fixed-effects model was chosen to analyze the regressive model and homozygote model, while other models were analyzed using the random-effects model. The results of Begg’s test (p > 0.05) showed no significant publication bias in the results of the regressive model and homozygote model.
Anzeige
The results showed no significant association between TNF-α 863C/A locus A and CAD susceptibility: the allelic model (A vs. C) (OR:0.803, 95% CI:0.584–1.103); the homozygote model (AA vs. CC) (OR:0.838, 95% CI:0.612–1.145); the dominant model (AA + CA vs. CC) (OR: 0.793, 95% CI:0.512–1.227); the regressive model (AA vs.CA + CC) (OR:0.828, 95% CI: 0.608–1.129); the heterozygote model (CA vs. CC) (OR: 0.805, 95% CI:0.584–1.103).
All the above results are presented in Fig. 7 and Table 5.
Table 5
Meta-analysis of TNF-α 863C/A polymorphisms and CAD susceptibility
Genetic Model
N (case/control)
OR(95%CI)
P*
I2
P#
P value
Begg
Egger
AA vs CC + CA
3144/4491
0.828 (0.608,1.129)
0.478
0.0%
0.234
0.466
0.016
AA+CA vs CC
3144/4491
0.793 (0.512,1.227)
0.000
93.3%
0.298
0.020
0.390
AA vs CC
3144/4491
0.838 (0.612,1.145)
0.450
0.0%
0.267
0.348
0.035
CA vs CC
3144/4491
0.805 (0.513,1.265)
0.000
93.3%
0.347
0.032
0.426
A vs C
3144/4491
0.803 (0.584,1.103)
0.000
90.6%
0.176
0.012
0.204
*P value of Heterogeneity chi-squared
#P value of Pooled statistic
×
Meta-analysis of TNF-α 1031 T/C polymorphisms and CAD susceptibility
In total, 9 studies with 3851 patients in the CAD group and 3936 controls reported on the association between TNF-α 1031 T/C and CAD susceptibility.
For studies with no significant heterogeneity (chi-squared test, P > 0.05 and I2 < 50%), the fixed-effects model was chosen to analyze all the comparison model except the regressive model and homozygote model. The results of Begg’s test (p > 0.05) showed no significant publication bias among the study results.
The results showed no significant association between TNF-α 1031 T/C locus C and CAD susceptibility: the allelic model (C vs. T) (OR:0.973, 95% CI:0.898–1.054); the homozygote model (CC vs. TT) (OR:0.999, 95% CI:0.666–1.498); the dominant model (CC + CT vs. TT) (OR: 0.945, 95% CI:0.860–1.039); regressive model (CCvs.TT+ CT) (OR: 1.020, 95% CI: 0.677–1.539); the heterozygote model (CT vs. TT) (OR: 0.929, 95% CI:0.842–1.025).
All the above results are presented in Fig. 8 and Table 6.
Table 6
Meta-analysis of TNF-α 1031 T/C polymorphisms and CAD susceptibility
Genetic Model
N (case/control)
OR(95%CI)
P*
I2
P#
P value
Begg
Egger
CC vs TT + CT
3781/3845
1.020 (0.677,1.539)
0.013
58.6%
0.923
0.602
0.458
CC + CT vs TT
3781/3845
0.945 (0.860,1.039)
0.476
0.0%
0.243
0.466
0.786
CC vs TT
3781/3845
0.999 (0.666,1.498)
0.018
56.5%
0.997
0.602
0.465
CT vs TT
3781/3845
0.929 (0.842,1.025)
0.401
4.1%
0.141
0.175
0.951
C vs T
3781/3845
0.973 (0.898,1.054)
0.248
21.9%
0.505
1.000
0.624
*P value of Heterogeneity chi-squared
#P value of Pooled statistic
×
Discussion
Atherosclerosis is the pathological basis of coronary heart disease, and inflammation plays a crucial role in the occurrence and development of atherosclerosis. Inflammation plays an important role in the formation, growth, rupture, and/or wear and tear of atherosclerotic plaques and the formation of blood clots. In particular, acute cardiovascular events such as heart failure, nausea and arrhythmia, cardiogenic shock and even cardiac arrest caused by plaque rupture and secondary acute thrombosis leading to complete occlusion of blood vessels are common clinical emergencies with sudden onset and high mortality. Therefore, the occurrence and development of coronary heart disease is a process of chronic inflammatory response.
TNF-α is an important proinflammatory cytokine mediating inflammatory response and immune regulatory response in vivo. TNF-α can affect the development of coronary heart disease through the following ways: [1] participation in the inflammatory response of atherosclerotic plaques, the formation and rupture of plaques, leading to coronary heart disease and even acute myocardial infarction [2]. Direct injury to vascular endothelial cells can increase their permeability, and blood cholesterol can easily penetrate the intima and deposit in the wall of the vessels [3]. Promotion of proto-oncogene transcription, production of platelet-derived growth factors, disruption of the balance between blood coagulation and anti-blood coagulation, and promotion of thrombosis [4]. Inhibiting lipoprotein enzyme activity is not conducive to lipid dissolution and deposition in the vascular wall, promoting the formation of arteriosclerosis and aggravating the damage of the vascular wall. TNF-α polymorphic loci are located in the promoter region of − 308, − 238, − 163, − 244,-857, − 836, − 1031 and other loci. The presence of these gene polymorphisms may affect gene transcription and expression levels and be associated with various diseases.
In previous studies, Fengtian et al. [35] included 14 studies and found no association between T-1031C, C-857 T and C-863A and CAD risk. Karely et al. [36] included 27 articles, and found a significant association between TNF-a G308A and CHD in the whole population, and between the variant G238A and CHD in the Asian population.
In our study, we found that TNF-α 308G/A locus A had no significant association with CAD susceptibility by the five models in the analysis of the overall population, Europeans, Africans, south Asians, and north Asians, which is contrary to the conclusion of Karely Pulido-Gomez. TNF-α 863C/A locus A and 1031 T/C locus C showed no significant association with CAD susceptibility, which is consistent with the conclusion of Fengtian HUANGFU. TNF-α 238G/A locus A had no significant association with CAD susceptibility in the overall population. However, TNF-α 238G/A locus A displayed significant association with higher CAD susceptibility in the subgroup of Europeans and north Asians. The association of TNF-α 238G/A in Asians is consistent with the study by Karely Pulido-Gomez. TNF-α 857C/T locus T had no significant association with CAD susceptibility in the analysis of the overall population and Europeans. In the north Asian population, TNF-α 857C/T locus T was associated with lower CAD susceptibility.
However, there are certain limitations to the present analysis, which are as follows: [1] only English and Chinese articles were included [2]; individual studies had different exclusion/inclusion criteria [3]; the severity of CAD was varied in different studies [4]; the number of included studies was limited, and some of the studies had a small sample size [5]; pooled data were analyzed, as individual patient data was not available, precluding more in-depth analyses.
Conclusion
Our results indicate that TNF-α 308G/A, 857C/T, 863C/A, and 1031 T/C are not associated with CAD susceptibility. TNF-α 238G/A locus A has significant association with CAD susceptibility In Europeans and north Asians, but has no significant association in the overall population. In the north Asian population, TNF-α 857C/T locus T was associated with lower CAD susceptibility. Larger-sample studies are required to confirm the association between TNF-α 238G/A and 857C/T and CAD susceptibility.
Acknowledgements
None.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
There is no competing interest.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.